A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms BOLERO-1
- Sponsors Novartis
- 17 May 2017 Planned End Date changed from 1 Jun 2017 to 30 May 2018.
- 17 May 2017 Planned primary completion date changed from 1 Jun 2017 to 30 May 2018.
- 18 Apr 2016 Results of a pooled biomarker analysis form BOLERO-1 and BOLERO-3 trials (n=549) published in the Journal of Clinical Oncology